
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5766043/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. Aids, 2022, 36, 205-214.	1.0	5
2	Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study. Infection, 2022, 50, 607-616.	2.3	5
3	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe, The, 2022, 3, e203-e214.	3.4	33
4	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	15.2	342
5	SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood Advances, 2022, 6, 1580-1584.	2.5	8
6	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. Infection, 2022, , 1.	2.3	0
7	Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals. Journal of Clinical Virology, 2022, 148, 105119.	1.6	10
8	CXCR3 Expression Pattern on CD4+ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue. Pathogens, 2022, 11, 483.	1.2	4
9	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
10	A missing link between SARSâ€CoVâ€⊋ and the eye?: ACE2 expression on the ocular surface. Journal of Medical Virology, 2021, 93, 78-79.	2.5	31
11	Plasma interferon-Î ³ -inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis. Infection, 2021, 49, 437-445.	2.3	4
12	No secret hiding place? Absence of SARS-CoV-2 on the ocular surface of 1145 hospitalized patients in a pandemic area. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1605-1608.	1.0	13
13	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms, 2021, 9, 733.	1.6	22
14	Swarm Learning for decentralized and confidential clinical machine learning. Nature, 2021, 594, 265-270.	13.7	375
15	Longâ€ l ived macrophage reprogramming drives spike proteinâ€mediated inflammasome activation in COVIDâ€19. EMBO Molecular Medicine, 2021, 13, e14150.	3.3	98
16	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host and Microbe, 2021, 29, 917-929.e4.	5.1	132
17	Web-based, rapid and contactless management of ambulatory patients for SARS-CoV-2-testing. BMC Infectious Diseases, 2021, 21, 535.	1.3	4
18	Protocol of the Cologne Corona Surveillance (CoCoS) Study– a prospective population-based cohort study. BMC Public Health, 2021, 21, 1295.	1.2	6

#	Article	IF	CITATIONS
19	Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Regional Health - Europe, The, 2021, 6, 100122.	3.0	452
20	Providing care in isolation while awaiting SARS-CoV-2 test results. Medicine (United States), 2021, 100, e26720.	0.4	0
21	The Alpha Variant (B.1.1.7) of SARS-CoV-2 in Children: First Experience from 3544 Nucleic Acid Amplification Tests in a Cohort of Children in Germany. Viruses, 2021, 13, 1600.	1.5	23
22	Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals. Journal of Clinical Microbiology, 2021, 59, e0089621.	1.8	55
23	Post-COVID syndrome: Turning convalescence into illness? – Authors' reply. Lancet Regional Health - Europe, The, 2021, 7, 100170.	3.0	3
24	Alveolar echinococcosis as a cause of vertebral osteomyelitis and soft tissue infection with recurrent cutaneous fistula formation. International Journal of Infectious Diseases, 2021, 114, 31-33.	1.5	1
25	Safe and effective pool testing for SARS-CoV-2 detection. Journal of Clinical Virology, 2021, 145, 105018.	1.6	9
26	Intensified adjunctive corticosteroid therapy for CNS tuberculomas. Infection, 2020, 48, 289-293.	2.3	6
27	Vertebral Osteomyelitis After Spine Surgery. Spine, 2020, 45, 1426-1434.	1.0	13
28	RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. Viruses, 2020, 12, 1045.	1.5	53
29	More than loss of taste and smell: burning watering eyes in coronavirus disease 2019. Clinical Microbiology and Infection, 2020, 26, 1560.e5-1560.e8.	2.8	23
30	Reply to Gourtsoyannis. Clinical Infectious Diseases, 2020, 71, 3018-3019.	2.9	6
31	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005–2017. Infection, 2020, 48, 723-733.	2.3	9
32	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	13.5	106
33	Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 71, 2262-2264.	2.9	127
34	Contrast-Enhanced Ultrasound for the Detection of Abdominal Complications in Infective Endocarditis: First Experience From a Prospective Cohort. Ultrasound in Medicine and Biology, 2020, 46, 2965-2971.	0.7	4
35	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Eurosurveillance, 2020, 25, .	3.9	18
36	Short Communication: Tracking Tregs: Translocation of CD49b/LAG-3 ⁺ Type 1 T Regulatory Cells to the Gut-Associated Lymphoid Tissue of HIV ⁺ Patients. AIDS Research and Human Retroviruses, 2019, 35, 247-250.	0.5	3

#	Article	lF	CITATIONS
37	HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?. Infection, 2019, 47, 293-300.	2.3	6
38	Severe disseminated tuberculosis in HIV-negative refugees. Lancet Infectious Diseases, The, 2019, 19, e352-e359.	4.6	19
39	Diagnostic challenges in infective endocarditis: is PET/CT the solution?. Infection, 2019, 47, 579-587.	2.3	15
40	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	13.7	392
41	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	15.2	195
42	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191.	15.2	399
43	The "Choosing Wisely―initiative in infectious diseases. Infection, 2017, 45, 263-268.	2.3	39
44	Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Eurosurveillance, 2017, 22, .	3.9	28
45	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	1.1	30
46	The "Choosing Wisely†initiative in infectious diseases. Infection, 2016, 44, 283-290.	2.3	19
47	Cytokine and Chemokine Signature in <i>Elite</i> Versus <i>Viremic Controllers</i> Infected with HIV. AIDS Research and Human Retroviruses, 2016, 32, 579-587.	0.5	15
48	Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection. Nature Immunology, 2016, 17, 593-603.	7.0	75
49	HIV-1 Integration Landscape during Latent and Active Infection. Cell, 2015, 160, 420-432.	13.5	393
50	Increased Frequency of CD49b/LAG-3+Type 1 Regulatory T Cells in HIV-Infected Individuals. AIDS Research and Human Retroviruses, 2015, 31, 1238-1246.	0.5	19
51	Sex differences in immune responses to infectious diseases. Infection, 2015, 43, 399-403.	2.3	135
52	Total chemical synthesis of human interferon alphaâ€2b via native chemical ligation. Journal of Peptide Science, 2015, 21, 554-560.	0.8	4
53	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491.	13.7	665
54	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	4.2	79

#	Article	IF	CITATIONS
55	Longitudinal Analysis of Distribution and Function of Plasmacytoid Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. Journal of Infectious Diseases, 2014, 209, 940-949.	1.9	46
56	CD161+ MAIT Cells Are Severely Reduced in Peripheral Blood and Lymph Nodes of HIV-Infected Individuals Independently of Disease Progression. PLoS ONE, 2014, 9, e111323.	1.1	57
57	Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. Journal of Leukocyte Biology, 2013, 94, 551-561.	1.5	57
58	HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation. Journal of the American Heart Association, 2013, 2, e000264.	1.6	59
59	Vγ2Vδ2 T Cells are Skewed Toward a Terminal Differentiation Phenotype in Untreated HIV Infection. Journal of Infectious Diseases, 2013, 208, 180-182.	1.9	3
60	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	4.2	156
61	CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology, 2011, 411, 32-40.	1.1	18
62	Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3 ⁺ T Regulatory Cells Correlates with Progressive Disease. Journal of Virology, 2011, 85, 1287-1297.	1.5	166
63	An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clinical Rheumatology, 2010, 29, 1169-1173.	1.0	52
64	Plasmacytoid Dendritic Cells Accumulate and Secrete Interferon Alpha in Lymph Nodes of HIV-1 Patients. PLoS ONE, 2010, 5, e11110.	1.1	77
65	Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opinion on Investigational Drugs, 2009, 18, 1773-1785.	1.9	6
66	Nucleoside-Free Boosted Double PI Regimen: Significant CD4+ T-Cell Recovery in Patients with Poor Immunologic Response Despite Virologic Suppression. Current HIV Research, 2008, 6, 555-559.	0.2	6
67	Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 522-530.	0.9	63
68	Effects of Low Habitual Cocoa Intake on Blood Pressure and Bioactive Nitric Oxide. JAMA - Journal of the American Medical Association, 2007, 298, 49.	3.8	418
69	Fatal cerebral lymphomatoid granulomatosis in an HIV-1-infected patient. Journal of Infection, 2007, 54, e175-e178.	1.7	14
70	Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. Journal of Clinical Virology, 2006, 37, 300-304.	1.6	28
71	Rapid Improvement of Liver Function in a Patient with HIV and Hepatitis B Coinfection Treated with Lamivudine and Tenofovir. Infection, 2006, 34, 234-235.	2.3	5
72	Safe and Effective Pool Testing for SARS-CoV-2 Detection. SSRN Electronic Journal, 0, , .	0.4	4

#	Article	IF	CITATIONS
73	Immundefizienz und -suppression: Patienten unbedingt impfen. Deutsches Ärzteblatt International, 0, , .	0.6	0